Aspire Biopharma (NASDAQ:ASBP) Issues Earnings Results

Aspire Biopharma (NASDAQ:ASBP) announced its quarterly earnings data on Thursday. The company reported ($1.22) earnings per share (EPS) for the quarter, FiscalAI reports. The business had revenue of $0.06 million for the quarter.

Aspire Biopharma Stock Performance

ASBP stock traded up $0.36 during mid-day trading on Friday, reaching $7.47. 1,299 shares of the stock traded hands, compared to its average volume of 349,303. Aspire Biopharma has a one year low of $3.31 and a one year high of $1,050.36. The stock has a market capitalization of $9.71 million, a PE ratio of -0.06 and a beta of 0.11. The business has a 50-day moving average price of $6.45 and a two-hundred day moving average price of $18.94.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aspire Biopharma in a report on Friday, July 17th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Hedge Funds Weigh In On Aspire Biopharma

Several hedge funds have recently bought and sold shares of the business. Jane Street Group LLC boosted its holdings in shares of Aspire Biopharma by 2,252.1% in the fourth quarter. Jane Street Group LLC now owns 688,143 shares of the company’s stock valued at $91,000 after purchasing an additional 658,886 shares during the period. XTX Topco Ltd increased its holdings in Aspire Biopharma by 853.2% during the 4th quarter. XTX Topco Ltd now owns 265,471 shares of the company’s stock worth $35,000 after purchasing an additional 237,620 shares during the period. Finally, CIBC Bancorp USA Inc. purchased a new position in Aspire Biopharma during the 3rd quarter worth $28,000. Institutional investors own 19.17% of the company’s stock.

Aspire Biopharma Company Profile

Aspire Biopharma Inc is a specialty pharmaceutical company dedicated to developing and commercializing inhaled therapeutics for cardiopulmonary emergencies and respiratory diseases. The firm leverages proprietary formulation and drug-delivery technologies to repurpose established active pharmaceutical ingredients, aiming to enhance onset of action and improve patient convenience in acute settings. Aspire’s focus on pulmonary administration differentiates its approach from traditional oral or injectable treatments for asthma, allergic reactions, and other respiratory conditions.

The company’s lead asset is a reformulated metered-dose inhaler version of epinephrine designed to serve as an over-the-counter or prescription rescue therapy for acute bronchospasm and anaphylaxis.